Exploring the efficacy of recombinant human pro-urokinase in catheter-directed thrombolysis for acute lower extremity deep venous thrombosis patients

Table 6 PTS incidence and venous patency at 6-Month Follow-Up

Outcome	Observation Group (n = 43)	Control Group (n = 42)	χ²	P-value
PTS Incidence	4 (9.3%)	11 (26.2%)	χ² = 4.512	0.034
Severe PTS	0 (0%)	3 (7.1%)	Fisher’s exact	0.048
Venous Patency	38 (88.4%)	30 (71.4%)	χ² = 4.021	0.045

ISSN: 1471-2261